|
1. Autologous Hematopoietic Stem Cell Transplantation
Patient-derived
Established care
|
Reconstitution of blood-forming systems after high-dose chemotherapy and treatment of selected hematological malignancies and severe blood disorders.
|
US: Established clinical procedure; collection, processing, storage, and administration remain subject to applicable tissue, blood, cellular-therapy, and healthcare rules.
EU/EEA: Governed through national competent authorities and applicable substance-of-human-origin, tissue, blood, and medicinal-product frameworks.
Japan and China: Established hospital-based practice with local requirements for cell collection, processing, traceability, and institutional oversight.
|
Leukapheresis or marrow collection, controlled-rate freezing where applicable, cryogenic storage, thawing, and bedside or hospital administration. Usually performed through qualified clinical facilities.
|
Donor/patient identification, chain of identity, chain of custody, cell count, viability, sterility or microbial control, hematopoietic potency or recovery indicators, controlled temperature records, and release authorization.
|
High clinical maturity for defined indications. Outcomes depend on disease type, conditioning regimen, cell dose, patient risk, and transplant-center capability.
|
Verify collection-site accreditation, validated cryopreservation procedures, emergency continuity plans, donor eligibility controls, electronic traceability, transport validation, and documented release criteria.
|
|
2. Allogeneic Mesenchymal Stromal Cell Products
Off-the-shelf potential
Advanced therapy
|
Investigational or indication-specific use in immune modulation, tissue repair, inflammatory disorders, and selected complications of transplantation.
|
US: Expanded cell products generally require an investigational pathway unless a specific authorization applies; minimal-manipulation and homologous-use rules are important.
EU/EEA: Frequently treated as advanced therapy medicinal products when substantially manipulated or used for a non-homologous function.
Japan and China: Requirements vary according to product characteristics, clinical use, and whether the program follows a medicinal-product or regulated medical-care pathway.
|
Qualified donor screening, tissue procurement, controlled isolation and expansion, closed or functionally closed processing, cryopreservation, and batch release. Master and working cell banks may be used.
|
Identity markers, viability, cell-count accuracy, sterility, mycoplasma, endotoxin, adventitious-agent testing, genetic stability, differentiation or immunomodulatory potency, residual-process-material testing, and stability.
|
Substantial clinical research exists, but efficacy is indication-specific and product-dependent. Clinical results should not be generalized across different cell sources, passages, doses, or manufacturing processes.
|
Request regulatory classification, donor-screening records, cell-bank characterization, comparability data after process changes, potency-assay validation, cold-chain qualification, and indication-specific clinical evidence.
|
|
3. Autologous Chondrocyte Implantation Products
Cartilage repair
Patient-specific
|
Repair of selected symptomatic cartilage defects, particularly focal articular-cartilage lesions, after appropriate patient evaluation.
|
US: Cell-based cartilage products may be regulated as biologics, human cells, tissues, or combination products depending on manipulation and intended use.
EU/EEA: Substantially manipulated or non-homologous products may fall under advanced therapy medicinal-product rules; national requirements also apply to tissue procurement and implantation.
Japan and China: Product classification, clinical evidence, facility controls, and hospital authorization requirements must be confirmed locally.
|
Biopsy collection, tissue transport, cell isolation and expansion, controlled seeding onto a scaffold or membrane where applicable, patient matching, release testing, and coordinated surgical implantation.
|
Cell identity, viability, sterility, mycoplasma, endotoxin, cell number, morphology, matrix-production or functional potency, scaffold characteristics, packaging integrity, and time-out-of-specification controls.
|
Established clinical concept for selected focal cartilage defects, but results are influenced by lesion size, patient age, rehabilitation, surgical technique, and product design.
|
Confirm biopsy-to-implant logistics, maximum manufacturing time, patient-specific labeling, deviation handling, validated transport conditions, surgeon training, rehabilitation protocols, and long-term outcome monitoring.
|
|
4. Decellularized Extracellular-Matrix Scaffolds
Biological scaffold
Tissue engineering
|
Structural support for soft-tissue, dermal, tendon, ligament, cardiovascular, or other repair applications, depending on the source tissue and intended use.
|
US: May be regulated as a human tissue, medical device, biologic, or combination product depending on processing, claims, and composition.
EU/EEA: Classification can fall under medical-device, tissue, or advanced-therapy frameworks; the intended use and degree of processing are decisive.
Japan and China: Local device, tissue, or combination-product classification must be confirmed before import or clinical use.
|
Controlled tissue sourcing, decellularization, washing, terminal or aseptic processing, shaping, drying or cryopreservation, packaging, and validated sterilization where compatible with matrix performance.
|
Residual cellular DNA, bioburden, sterility, endotoxin, collagen and matrix composition, mechanical strength, porosity, degradation profile, cytotoxicity, residual detergent, packaging integrity, and shelf life.
|
Clinical maturity varies widely by anatomy and indication. Evidence is strongest where the scaffold has a clearly defined structural role and an established surgical application.
|
Review source-tissue eligibility, animal-origin risks where relevant, viral and transmissible-agent controls, sterilization validation, mechanical testing, lot consistency, storage conditions, and claims-to-evidence alignment.
|
|
5. Synthetic or Bioactive Tissue-Engineering Scaffolds
Resorbable materials
Combination potential
|
Guided repair or regeneration in bone, cartilage, skin, nerve, and other tissues; may be used alone or combined with cells, growth factors, or autologous tissue.
|
US: Frequently evaluated under medical-device rules when the primary intended action is physical or structural; cell- or drug-containing versions may require combination-product review.
EU/EEA: Usually assessed under medical-device rules unless biological, pharmacological, or cellular functions change the principal mode of action.
Japan and China: Classification depends on material composition, degradation, biological claims, and any incorporated cells or active substances.
|
Polymer or ceramic synthesis, controlled fabrication, surface treatment, additive manufacturing where applicable, packaging, sterilization, and batch-specific dimensional and mechanical release.
|
Chemical identity, residual monomers or solvents, porosity, pore-size distribution, compressive or tensile strength, degradation rate, particulate profile, cytotoxicity, sensitization, irritation, sterility, and packaging integrity.
|
Mature for several structural applications, while advanced bioactive and cell-containing designs remain more indication- and claim-dependent.
|
Check raw-material specifications, supplier change controls, extractables and leachables, sterilization impact, shelf-life data, mechanical equivalence, animal and clinical evidence, and compatibility with the intended surgical technique.
|
|
6. Platelet-Rich Plasma and Autologous Blood-Derived Preparations
Autologous
Point-of-care
|
Selected musculoskeletal, tendon, ligament, wound, and soft-tissue applications. Clinical benefit varies by preparation method and indication.
|
US: Classification depends on the preparation system, claims, manipulation, and intended use; many systems are used as point-of-care procedures rather than as broadly approved regenerative medicines.
EU/EEA: Device, tissue, blood, or national healthcare rules may apply depending on the system and clinical setting.
Japan and China: Local rules for blood handling, medical devices, hospital procedures, and promotional claims must be verified.
|
Point-of-care blood collection, centrifugation or separation, controlled transfer, and immediate administration. Closed systems can reduce contamination and operator variability.
|
Platelet concentration, leukocyte profile, red-cell carryover, activation method, sterility or aseptic controls, anticoagulant identity, device functionality, operator training, and procedure documentation.
|
Widely used, but clinical evidence is heterogeneous. Outcomes are affected by preparation protocol, dose, injection technique, patient selection, and comparator treatment.
|
Define the intended indication and claims, standardize preparation parameters, validate operator training, confirm device registration, document patient eligibility, and avoid unsupported disease-treatment or tissue-regeneration claims.
|
|
7. Extracellular Vesicle and Exosome-Based Products
Emerging platform
Research-focused
|
Investigational delivery of biologically active cargo for tissue repair, inflammation control, or drug-delivery research. Routine clinical use is not broadly established across major markets.
|
US: Products marketed to treat disease or modify biological function generally require appropriate regulatory authorization; unapproved products cannot be promoted as proven treatments.
EU/EEA: Classification is product- and claim-dependent and may involve medicinal-product, biologic, tissue, or medical-device rules.
Japan and China: Regulatory status is evolving; sponsors should obtain formal classification and clinical-use advice before import, clinical testing, or commercialization.
|
Qualified source-cell or tissue control, serum or media qualification, isolation and purification, concentration, sterile processing, frozen or lyophilized presentation, and highly controlled storage and shipping.
|
Particle size and concentration, particle-to-protein ratio, vesicle markers, cargo or potency assay, sterility, mycoplasma, endotoxin, residual host-cell proteins and DNA, adventitious agents, aggregation, and stability.
|
Early-stage and indication-specific. Analytical standardization, mechanism-linked potency, dose selection, and reproducible manufacturing remain major development challenges.
|
Require formal regulatory classification, source-material traceability, orthogonal identity testing, validated potency assays, contaminant controls, batch comparability, clinical-trial authorization, and strict review of marketing claims.
|
